Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial (vol 374, pg 1503, 2009)

被引：0
|
作者：
Comi, G.
Martinelli, V
Rodegher, M.
机构：
来源：
LANCET | 2010年 / 375卷 / 9724期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1436 / 1436
页数：1
相关论文
共 50 条
  • [1] Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
    Comi, G.
    Martinelli, V.
    Rodegher, M.
    Moiola, L.
    Bajenaru, O.
    Carra, A.
    Elovaara, I.
    Fazekas, F.
    Hartung, H. P.
    Hillert, J.
    King, J.
    Komoly, S.
    Lubetzki, C.
    Montalban, X.
    Myhr, K. M.
    Ravnborg, M.
    Rieckmann, P.
    Wynn, D.
    Young, C.
    Filippi, M.
    LANCET, 2009, 374 (9700): : 1503 - 1511
  • [2] Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome: subgroup analyses
    Comi, Giancarlo
    Carra, Adriana
    Fazekas, Franz
    Rieckmann, Peter
    Bajenaru, O.
    Hillert, Jan
    Elovaara, Irina
    Young, Carolyn
    Wynn, Daniel
    King, John
    Lubetzki, Catherine
    Hartung, Hans-Peter
    Myhr, Kjell-Morten
    Montalban, Xavier
    Komoly, Samuel
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S38 - S38
  • [3] Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome suggestive of MS
    Comi, G.
    Filippi, M.
    JOURNAL OF NEUROLOGY, 2008, 255 : 10 - 10
  • [4] Glatiramer acetate delayed conversion to multiple sclerosis in patients with clinically isolated syndrome
    Paulseth, J. E. Rick
    ANNALS OF INTERNAL MEDICINE, 2010, 152 (02)
  • [5] Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndromes (CIS)
    Comi, Giancarlo
    Filippi, Massimo
    NEUROLOGY, 2008, 71 (02) : 153 - 153
  • [6] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study (vol 374, pg 1606, 2009)
    Astrup, A.
    Roessner, S.
    Van Gaal, L.
    LANCET, 2010, 375 (9719): : 984 - 984
  • [7] Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
    Wolinsky, Jerry S.
    Narayana, Pormada A.
    O'Connor, Paul
    Coyle, Patricia K.
    Ford, Corey
    Johnson, Kenneth
    Miller, Aaron
    Pardo, Lillian
    Kadosh, Shaul
    Laclkani, David
    ANNALS OF NEUROLOGY, 2007, 61 (01) : 14 - 24
  • [8] CSF Abnormalities and the Risk of Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndromes: A Meta-Analysis of Placebo Patients from the Interferon Beta and Glatiramer Acetate Clinically Isolated Syndrome Trials
    Riley, Claire
    Smrtka, Jennifer
    Khalid, Shahram
    Wang, Shuang
    Tullman, Mark J.
    NEUROLOGY, 2009, 72 (11) : A78 - A78
  • [9] A prospective study of the time to conversion to clinically definite multiple sclerosis in 172 Greek patients with clinically isolated syndrome
    Koutsis, Georgios
    Evangelopoulos, Maria Elephtheria
    Karachalios, Georgios
    Andreadou, Elisabeth
    Mandellos, Dimitris
    Vassilopoulos, Demetris
    Sfagos, Constantinos
    MULTIPLE SCLEROSIS, 2008, 14 : S72 - S72
  • [10] A randomised, double-blind, placebo-controlled study of fluoxetine for relapsing multiple sclerosis
    Mostert, I. P.
    Admilaal-Behlou, E.
    Hoogduin, I. M.
    Luyetidijk, J.
    Heersema, D. J.
    van Buchem, M. A.
    de Keyser, J.
    MULTIPLE SCLEROSIS, 2007, 13 : S25 - S26
12345